LU92126B1 - Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale - Google Patents

Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Info

Publication number
LU92126B1
LU92126B1 LU92126A LU92126A LU92126B1 LU 92126 B1 LU92126 B1 LU 92126B1 LU 92126 A LU92126 A LU 92126A LU 92126 A LU92126 A LU 92126A LU 92126 B1 LU92126 B1 LU 92126B1
Authority
LU
Luxembourg
Prior art keywords
neurodegenerative
neuronal
disorder
disease
prevention
Prior art date
Application number
LU92126A
Other languages
English (en)
Original Assignee
Cesa Alliance Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to LU92126A priority Critical patent/LU92126B1/fr
Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa
Priority to AU2013369491A priority patent/AU2013369491B2/en
Priority to PE2015001180A priority patent/PE20151424A1/es
Priority to MX2015008520A priority patent/MX369590B/es
Priority to SG11201504744WA priority patent/SG11201504744WA/en
Priority to BR112015015509-0A priority patent/BR112015015509B1/pt
Priority to MA38307A priority patent/MA38307B1/fr
Priority to NZ710131A priority patent/NZ710131A/en
Priority to UAA201507037A priority patent/UA117822C2/uk
Priority to KR1020157020805A priority patent/KR102104155B1/ko
Priority to MYPI2015702083A priority patent/MY171832A/en
Priority to PCT/EP2013/076936 priority patent/WO2014102090A1/fr
Priority to EP13808014.8A priority patent/EP2938337A1/fr
Priority to EA201591021A priority patent/EA029650B1/ru
Priority to CA2895429A priority patent/CA2895429C/fr
Priority to HK16102495.8A priority patent/HK1214517A1/zh
Priority to JP2015550024A priority patent/JP6699961B2/ja
Priority to CN201380069044.3A priority patent/CN104884052B/zh
Priority to US14/758,343 priority patent/US9284250B2/en
Priority to ARP130105072A priority patent/AR094318A1/es
Priority to UY0001035253A priority patent/UY35253A/es
Priority to JOP/2013/0390A priority patent/JO3483B1/ar
Priority to TW102148993A priority patent/TWI590819B/zh
Application granted granted Critical
Publication of LU92126B1 publication Critical patent/LU92126B1/fr
Priority to TNP2015000275A priority patent/TN2015000275A1/fr
Priority to PH12015501402A priority patent/PH12015501402A1/en
Priority to IL239622A priority patent/IL239622B/en
Priority to CL2015001881A priority patent/CL2015001881A1/es
Priority to ZA2015/05057A priority patent/ZA201505057B/en
Priority to US15/069,118 priority patent/US9611205B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LU92126A 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale LU92126B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
LU92126A LU92126B1 (fr) 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
HK16102495.8A HK1214517A1 (zh) 2012-12-31 2013-12-17 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用於预防及治疗认知、神经退行性或神经元疾病
MX2015008520A MX369590B (es) 2012-12-31 2013-12-17 4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal.
SG11201504744WA SG11201504744WA (en) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
BR112015015509-0A BR112015015509B1 (pt) 2012-12-31 2013-12-17 Composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal
MA38307A MA38307B1 (fr) 2012-12-31 2013-12-17 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
NZ710131A NZ710131A (en) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
UAA201507037A UA117822C2 (uk) 2012-12-31 2013-12-17 4-гідрокси-2-метил-5-(пропан-2-іліден)циклогекс-3-енекарбальдегід у профілактиці та лікуванні когнітивних, нейродегенеративних або нейронних захворювань
KR1020157020805A KR102104155B1 (ko) 2012-12-31 2013-12-17 인지성, 신경퇴행성 또는 뉴런성 질환의 예방 및 치료를 위한 4-히드록시-2-메틸-5-(프로판-2-일리덴)시클로헥스-3-엔카르브알데히드
MYPI2015702083A MY171832A (en) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PCT/EP2013/076936 WO2014102090A1 (fr) 2012-12-31 2013-12-17 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
EP13808014.8A EP2938337A1 (fr) 2012-12-31 2013-12-17 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
EA201591021A EA029650B1 (ru) 2012-12-31 2013-12-17 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
CA2895429A CA2895429C (fr) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde pour la prevention et le traitement d'une maladie cognitive, neurodegenerative ou neuronale
AU2013369491A AU2013369491B2 (en) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
JP2015550024A JP6699961B2 (ja) 2012-12-31 2013-12-17 認知の、神経変性の、または神経の疾患の予防および治療のための４−ヒドロキシ−２−メチル−５−（プロパン−２−イリデン）シクロヘキサ−３−エンカルバルデヒド
PE2015001180A PE20151424A1 (es) 2012-12-31 2013-12-17 Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
US14/758,343 US9284250B2 (en) 2012-12-31 2013-12-17 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
CN201380069044.3A CN104884052B (zh) 2012-12-31 2013-12-17 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用于预防及治疗认知、神经退行性或神经元疾病
ARP130105072A AR094318A1 (es) 2012-12-31 2013-12-27 Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal
JOP/2013/0390A JO3483B1 (ar) 2012-12-31 2013-12-30 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
TW102148993A TWI590819B (zh) 2012-12-31 2013-12-30 認知、神經退化或神經元失調或疾病之預防及治療用醫藥化合物
UY0001035253A UY35253A (es) 2012-12-31 2013-12-30 Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o una enfermedad cogniti vos, neurodegenerativos o neuronales
TNP2015000275A TN2015000275A1 (fr) 2012-12-31 2015-06-16 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PH12015501402A PH12015501402A1 (en) 2012-12-31 2015-06-18 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
IL239622A IL239622B (en) 2012-12-31 2015-06-24 Preparations for the treatment of neurodegenerative diseases
CL2015001881A CL2015001881A1 (es) 2012-12-31 2015-06-30 Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
ZA2015/05057A ZA201505057B (en) 2012-12-31 2015-07-14 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive ,neurodegenerative or neuronal disease
US15/069,118 US9611205B2 (en) 2012-12-31 2016-03-14 Pharmaceutical compound for the prevention and treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU92126A LU92126B1 (fr) 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Publications (1)

Publication Number Publication Date
LU92126B1 true LU92126B1 (fr) 2014-07-01

Family

ID=47470067

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92126A LU92126B1 (fr) 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Country Status (28)

Country Link
US (2) US9284250B2 (fr)
EP (1) EP2938337A1 (fr)
JP (1) JP6699961B2 (fr)
KR (1) KR102104155B1 (fr)
CN (1) CN104884052B (fr)
AR (1) AR094318A1 (fr)
AU (1) AU2013369491B2 (fr)
BR (1) BR112015015509B1 (fr)
CA (1) CA2895429C (fr)
CL (1) CL2015001881A1 (fr)
EA (1) EA029650B1 (fr)
HK (1) HK1214517A1 (fr)
IL (1) IL239622B (fr)
JO (1) JO3483B1 (fr)
LU (1) LU92126B1 (fr)
MA (1) MA38307B1 (fr)
MX (1) MX369590B (fr)
MY (1) MY171832A (fr)
NZ (1) NZ710131A (fr)
PE (1) PE20151424A1 (fr)
PH (1) PH12015501402A1 (fr)
SG (1) SG11201504744WA (fr)
TN (1) TN2015000275A1 (fr)
TW (1) TWI590819B (fr)
UA (1) UA117822C2 (fr)
UY (1) UY35253A (fr)
WO (1) WO2014102090A1 (fr)
ZA (1) ZA201505057B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
CN110475853A (zh) * 2017-01-13 2019-11-19 益福生医股份有限公司 新颖乳酸菌及其应用
KR102017415B1 (ko) * 2018-02-13 2019-09-02 연세대학교 산학협력단 뇌 신경 손상 완화용 조성물
CN108813453A (zh) * 2018-05-23 2018-11-16 青岛大学 一种防治帕金森病的食用组合物
ES2972465T3 (es) 2019-12-02 2024-06-12 Philip Morris Products Sa Dispositivo de narguile con canales

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068576A1 (fr) * 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Composes dermatologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1511520A (zh) * 2002-12-31 2004-07-14 �й�ҽѧ��ѧԺҩ���о��� 丁二酸酯衍生物治疗痴呆症的用途
RU2005131845A (ru) * 2003-03-14 2006-02-10 Мерк Шарп энд Домэ Лимитед (GB) Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068576A1 (fr) * 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Composes dermatologiques

Also Published As

Publication number Publication date
JP2016505600A (ja) 2016-02-25
UY35253A (es) 2014-07-31
EA029650B1 (ru) 2018-04-30
UA117822C2 (uk) 2018-10-10
KR20150102117A (ko) 2015-09-04
BR112015015509B1 (pt) 2021-11-30
CA2895429C (fr) 2019-04-16
EA201591021A1 (ru) 2016-01-29
KR102104155B1 (ko) 2020-04-24
BR112015015509A2 (pt) 2017-07-11
PH12015501402B1 (en) 2015-09-07
HK1214517A1 (zh) 2016-07-29
MA38307B1 (fr) 2017-11-30
US9611205B2 (en) 2017-04-04
WO2014102090A1 (fr) 2014-07-03
PE20151424A1 (es) 2015-10-15
MA38307A1 (fr) 2016-12-30
US20150361020A1 (en) 2015-12-17
TN2015000275A1 (fr) 2016-10-03
PH12015501402A1 (en) 2015-09-07
CA2895429A1 (fr) 2014-07-03
US20160194266A1 (en) 2016-07-07
AU2013369491B2 (en) 2018-04-26
NZ710131A (en) 2019-08-30
IL239622A0 (en) 2015-08-31
MY171832A (en) 2019-11-01
AU2013369491A1 (en) 2015-08-06
US9284250B2 (en) 2016-03-15
IL239622B (en) 2018-12-31
TWI590819B (zh) 2017-07-11
JO3483B1 (ar) 2020-07-05
MX369590B (es) 2019-11-13
CN104884052B (zh) 2021-06-25
SG11201504744WA (en) 2015-07-30
CL2015001881A1 (es) 2015-11-06
JP6699961B2 (ja) 2020-05-27
AU2013369491A2 (en) 2015-08-13
TW201431550A (zh) 2014-08-16
EP2938337A1 (fr) 2015-11-04
ZA201505057B (en) 2016-07-27
CN104884052A (zh) 2015-09-02
AR094318A1 (es) 2015-07-29
MX2015008520A (es) 2015-09-10

Similar Documents

Publication Publication Date Title
EP3552611A4 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant un polymorphe cristallin d'hexoxyde de tétraarsenic
EP2911664A4 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
EP2683382A4 (fr) Régimes posologiques pour le traitement de la maladie de fabry
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
EP2889032A4 (fr) Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole
EP2818481A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP3395364A4 (fr) Médicament contenant un inhibiteur de caspase pour le traitement ou la prévention de trouble provoqué par tgf- , et son application
EP2844279A4 (fr) Schéma posologique pour le traitement de la maladie de pompe
EP2800578A4 (fr) Signalisation de slit-robo pour le diagnostic et le traitement d'une maladie rénale
EP3481385C0 (fr) Système d'administration de médicament pulsatile pour le traitement de l'akinésie matinale
EP3607963A4 (fr) Médicament thérapeutique pour maladie fibreuse
EP2857007A4 (fr) Composition pharmaceutique contenant un dérivé de verbénone pour le traitement ou la prévention d'une maladie neurodégénérative
LU92126B1 (fr) Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
EP2959903A4 (fr) Médicament pour le traitement de maladie des yeux
EP2857037A4 (fr) Agent de prévention et/ou de traitement d'une douleur neuropathique périphérique causée par un médicament anticancéreux
EP3324944A4 (fr) Systèmes d'administration de médicaments intravitréens pour le traitement d'états oculaires
EP3730144A4 (fr) Agent pour le traitement d'une maladie du système nerveux
EP2999444A4 (fr) Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
EP2962693A4 (fr) Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
FR3005419B1 (fr) Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux
EP3329929A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire
EP3454912A4 (fr) Méthodes de traitement ayant une toxicité médicamenteuse réduite et méthodes d'identification de la nuisibilité de médicaments prescrits pour un patient
EP3344640A4 (fr) Dérivés d'aminoglycoside et leurs utilisations dans le traitement de troubles génétiques
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives